| Not Yet Recruiting | Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial NCT07371897 | Sun Yat-sen University | Phase 3 |
| Recruiting | GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Sing NCT07457281 | West China Hospital | Phase 1 |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377 | EpiBiologics | Phase 1 |
| Recruiting | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurre NCT06769698 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC NCT07465276 | Dana-Farber Cancer Institute | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell NCT07393477 | Sir Run Run Shaw Hospital | Phase 2 |
| Recruiting | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cel NCT07190755 | Centre Henri Becquerel | N/A |
| Not Yet Recruiting | [18F]-AraG PET Imaging in LA HNSCC NCT07168785 | Indiana University | EARLY_Phase 1 |
| Recruiting | AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 | Akeso | Phase 1 / Phase 2 |
| Recruiting | [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas NCT06794372 | John O. Prior | Phase 2 |
| Not Yet Recruiting | Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET NCT06482307 | University Medical Center Groningen | Phase 1 / Phase 2 |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma NCT06673693 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Exercise Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC) NCT06839014 | Our Lady of the Lake Hospital | N/A |
| Not Yet Recruiting | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects with HPV Positive HNSCC. NCT06797986 | Cellid Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treat NCT06869473 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Not Yet Recruiting | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care NCT06814067 | Fudan University | Phase 2 |
| Recruiting | Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surg NCT06607406 | Wake Forest University Health Sciences | N/A |
| Not Yet Recruiting | Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squ NCT06714266 | Shandong Cancer Hospital and Institute | Phase 2 |
| Not Yet Recruiting | A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadju NCT06530914 | Lei Liu | Phase 2 |
| Recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezo NCT06332755 | LG Chem | Phase 1 |
| Active Not Recruiting | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC NCT06295731 | Inhibrx Biosciences, Inc | Phase 2 / Phase 3 |
| Recruiting | Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma NCT06630780 | Sun Yat-sen University | N/A |
| Unknown | Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting In NCT06102447 | Sichuan Cancer Hospital and Research Institute | N/A |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally A NCT05473156 | AP Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Withdrawn | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC NCT04849377 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Active Not Recruiting | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 8368 NCT05249426 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483 | Exelixis | Phase 1 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Terminated | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid NCT04799054 | Ascendis Pharma Oncology Division A/S | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Hea NCT04603248 | Yonsei University | N/A |
| Completed | Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) NCT04220866 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advance NCT04215978 | BeiGene | Phase 1 |
| Recruiting | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab NCT04080804 | Dan Zandberg | Phase 2 |
| Active Not Recruiting | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 | Genmab | Phase 1 / Phase 2 |
| Completed | Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma NCT04284540 | Icahn School of Medicine at Mount Sinai | N/A |
| Withdrawn | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) NCT03114280 | Centre Antoine Lacassagne | Phase 1 / Phase 2 |
| Terminated | A Phase 1 Study of [225Ac]-FPI-1434 Injection NCT03746431 | Fusion Pharmaceuticals Inc. | Phase 1 |
| Completed | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors NCT03811652 | MedImmune LLC | Phase 1 |
| Active Not Recruiting | SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma NCT03546582 | RTOG Foundation, Inc. | Phase 2 |
| Completed | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Adva NCT03735628 | Bayer | Phase 1 |
| Completed | Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and N NCT03268993 | University of Pittsburgh | N/A |
| Recruiting | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or NCT03556228 | VM Oncology, LLC | Phase 1 / Phase 2 |
| Terminated | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC NCT03276819 | Centre Leon Berard | N/A |
| Withdrawn | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA NCT02211027 | Robert Ferris | Phase 1 |
| Completed | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionall NCT02764593 | RTOG Foundation, Inc. | Phase 1 |
| Completed | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone i NCT02684253 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma NCT00911326 | Navidea Biopharmaceuticals | Phase 3 |